Novo Nordisk A/S (NYSE:NVO) Shares Down 1.3%

Shares of Novo Nordisk A/S (NYSE:NVO) were down 1.3% during mid-day trading on Monday . The stock traded as low as $134.62 and last traded at $135.23. Approximately 715,256 shares traded hands during mid-day trading, a decline of 84% from the average daily volume of 4,404,311 shares. The stock had previously closed at $136.97.

Analyst Ratings Changes

NVO has been the subject of a number of research analyst reports. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a report on Monday, August 19th. StockNews.com lowered Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Monday, August 19th. Argus raised their price target on shares of Novo Nordisk A/S from $125.00 to $160.00 and gave the company a “buy” rating in a report on Monday, June 10th. The Goldman Sachs Group started coverage on shares of Novo Nordisk A/S in a report on Thursday, May 30th. They set a “buy” rating and a $156.00 price objective for the company. Finally, BMO Capital Markets dropped their target price on shares of Novo Nordisk A/S from $170.00 to $160.00 and set an “outperform” rating on the stock in a report on Thursday, August 8th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $145.17.

Novo Nordisk A/S Trading Down 1.2 %

The stock has a fifty day moving average of $136.22 and a 200 day moving average of $131.66. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.50 and a current ratio of 0.70. The company has a market capitalization of $607.21 billion, a P/E ratio of 46.58, a PEG ratio of 1.33 and a beta of 0.41.

Novo Nordisk A/S Cuts Dividend

The company also recently declared a semi-annual dividend, which will be paid on Monday, August 26th. Shareholders of record on Friday, August 16th will be issued a dividend of $0.5126 per share. This represents a yield of 0.7%. The ex-dividend date is Friday, August 16th. Novo Nordisk A/S’s dividend payout ratio is currently 24.83%.

Institutional Investors Weigh In On Novo Nordisk A/S

A number of institutional investors have recently bought and sold shares of NVO. Charles Schwab Investment Management Inc. lifted its stake in Novo Nordisk A/S by 38.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 94,544 shares of the company’s stock worth $9,781,000 after purchasing an additional 26,067 shares in the last quarter. McKinley Carter Wealth Services Inc. increased its stake in Novo Nordisk A/S by 37.0% in the 4th quarter. McKinley Carter Wealth Services Inc. now owns 60,356 shares of the company’s stock worth $6,244,000 after acquiring an additional 16,293 shares during the last quarter. Bank of New Hampshire raised its holdings in shares of Novo Nordisk A/S by 1,356.8% during the 1st quarter. Bank of New Hampshire now owns 13,257 shares of the company’s stock worth $1,702,000 after acquiring an additional 12,347 shares in the last quarter. Cim LLC bought a new position in shares of Novo Nordisk A/S during the 4th quarter valued at approximately $23,547,000. Finally, Burford Brothers Inc. bought a new stake in Novo Nordisk A/S in the fourth quarter worth $1,045,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.